Mechanisms of Metastatic Colorectal Cancer

Overview

Journal Nat Rev Gastroenterol Hepatol

Specialty Gastroenterology

Date 2024 May 28

PMID 38806657

Authors

Adria Canellas-Socias

Elena Sancho

Eduard Batlle

Affiliations

Soon will be listed here.

Abstract

Despite extensive research and improvements in understanding colorectal cancer (CRC), its metastatic form continues to pose a substantial challenge, primarily owing to limited therapeutic options and a poor prognosis. This Review addresses the emerging focus on metastatic CRC (mCRC), which has historically been under-studied compared with primary CRC despite its lethality. We delve into two crucial aspects: the molecular and cellular determinants facilitating CRC metastasis and the principles guiding the evolution of metastatic disease. Initially, we examine the genetic alterations integral to CRC metastasis, connecting them to clinically marked characteristics of advanced CRC. Subsequently, we scrutinize the role of cellular heterogeneity and plasticity in metastatic spread and therapy resistance. Finally, we explore how the tumour microenvironment influences metastatic disease, emphasizing the effect of stromal gene programmes and the immune context. The ongoing research in these fields holds immense importance, as its future implications are projected to revolutionize the treatment of patients with mCRC, hopefully offering a promising outlook for their survival.

Citing Articles

Exosomal miR-92a-3p modulates M2 macrophage polarization in colorectal cancer: implications for tumor migration and angiogenesis.

Zhao W, Wu Y, Wang Y, Li T, Liu Q, Hou Z Med Oncol. 2025; 42(4):96.

PMID: 40059261 DOI: 10.1007/s12032-025-02635-2.

Invasion and metastasis in cancer: molecular insights and therapeutic targets.

Li Y, Liu F, Cai Q, Deng L, OuYang Q, Zhang X Signal Transduct Target Ther. 2025; 10(1):57.

PMID: 39979279 PMC: 11842613. DOI: 10.1038/s41392-025-02148-4.

Shaping the microenvironment in peritoneal metastases.

Ren Q, Vermeulen L Nat Cancer. 2025; .

PMID: 39966609 DOI: 10.1038/s43018-024-00878-y.

Molecular principles underlying aggressive cancers.

Nussinov R, Yavuz B, Jang H Signal Transduct Target Ther. 2025; 10(1):42.

PMID: 39956859 PMC: 11830828. DOI: 10.1038/s41392-025-02129-7.

Trypsin-instructed bioactive peptide nanodrugs with cascading transformations to improve chemotherapy against colon cancer.

Wu C, Zhang X, Wang M, Sun J, Chen J, Guan Y J Nanobiotechnology. 2025; 23(1):66.

PMID: 39891144 PMC: 11784115. DOI: 10.1186/s12951-025-03143-1.

References

Dekker E, Tanis P, Vleugels J, Kasi P, Wallace M . Colorectal cancer. Lancet. 2019; 394(10207):1467-1480. DOI: 10.1016/S0140-6736(19)32319-0. View

Siegel R, Wagle N, Cercek A, Smith R, Jemal A . Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023; 73(3):233-254. DOI: 10.3322/caac.21772. View

Douillard J, Oliner K, Siena S, Tabernero J, Burkes R, Barugel M . Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013; 369(11):1023-34. DOI: 10.1056/NEJMoa1305275. View

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J . Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 34(1):10-32. DOI: 10.1016/j.annonc.2022.10.003. View

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Fearon E, Vogelstein B . A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759-67. DOI: 10.1016/0092-8674(90)90186-i. View

Lannagan T, Jackstadt R, Leedham S, Sansom O . Advances in colon cancer research: in vitro and animal models. Curr Opin Genet Dev. 2021; 66:50-56. PMC: 7985292. DOI: 10.1016/j.gde.2020.12.003. View

10.

Batlle E, Clevers H . Cancer stem cells revisited. Nat Med. 2017; 23(10):1124-1134. DOI: 10.1038/nm.4409. View

11.

Tilg H, Adolph T, Gerner R, Moschen A . The Intestinal Microbiota in Colorectal Cancer. Cancer Cell. 2018; 33(6):954-964. DOI: 10.1016/j.ccell.2018.03.004. View

12.

Kuipers E, Grady W, Lieberman D, Seufferlein T, Sung J, Boelens P . Colorectal cancer. Nat Rev Dis Primers. 2016; 1:15065. PMC: 4874655. DOI: 10.1038/nrdp.2015.65. View

13.

Rahbari N, Carr P, Jansen L, Chang-Claude J, Weitz J, Hoffmeister M . Time of Metastasis and Outcome in Colorectal Cancer. Ann Surg. 2017; 269(3):494-502. DOI: 10.1097/SLA.0000000000002564. View

14.

Chen K, Collins G, Wang H, Toh J . Pathological Features and Prognostication in Colorectal Cancer. Curr Oncol. 2021; 28(6):5356-5383. PMC: 8700531. DOI: 10.3390/curroncol28060447. View

15.

Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll H . A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015; 14(1):1-10. DOI: 10.1016/j.clcc.2014.11.002. View

16.

Kopetz S, Chang G, Overman M, Eng C, Sargent D, Larson D . Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009; 27(22):3677-83. PMC: 2720081. DOI: 10.1200/JCO.2008.20.5278. View

17.

Pastorino U, Buyse M, Friedel G, Ginsberg R, Girard P, Goldstraw P . Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997; 113(1):37-49. DOI: 10.1016/s0022-5223(97)70397-0. View

18.

Lipsyc M, Yaeger R . Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol. 2015; 6(6):645-9. PMC: 4671855. DOI: 10.3978/j.issn.2078-6891.2015.045. View

19.

Yaeger R, Chatila W, Lipsyc M, Hechtman J, Cercek A, Sanchez-Vega F . Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell. 2018; 33(1):125-136.e3. PMC: 5765991. DOI: 10.1016/j.ccell.2017.12.004. View

20.

MOERTEL C, Fleming T, Macdonald J, Haller D, Laurie J, Goodman P . Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990; 322(6):352-8. DOI: 10.1056/NEJM199002083220602. View